The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin
Nathan A. Brooks(Eli Lilly (United States)), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Yu Shen(University of Florida), Supriya Nagaraju(The University of Texas MD Anderson Cancer Center), Andrea Kokorovic(Dalhousie University), Justin T. Matulay(Levine Cancer Institute), Roger Li(Unknown), Weranja Ranasinghe(The University of Texas MD Anderson Cancer Center), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Lian-Chen Xiao(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 22
Related Papers
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517